Identification of Prostate-Specific G-Protein Coupled Receptor as a Tumor Antigen Recognized by CD8+ T Cells for Cancer Immunotherapy

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Matsueda, Satoko ^a   Wang, Mingjun ^a,b   Weng, Jinsheng ^a   Li, Ying ^a   Yin, Bingnan ^b   Zou, Jia ^a,b   Li, Qingtian ^a,b   Zhao, Wei ^a,b   Peng, Weiyi ^a   Legras, Xavier ^a   Loo, Christopher ^b   Wang, Rong Fu ^a,b,c   Wang, Helen Y ^a,b,c  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; HLA A2 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 1; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 10; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 11; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 12; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 13; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 14; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 15; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 16; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 17; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 18; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 19; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 2; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 20; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 21; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 22; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 23; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 24; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 3; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 4; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 5; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 7; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN MOTIF;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERFERON-GAMMA; MALE; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; RECEPTORS, ODORANT; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84866707719     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045756     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA: a cancer journal for clinicians 61: 69-90.
2. Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, et al. (2012) Current vaccination strategies for prostate cancer. European urology 61: 290-306.
3. Drake CG, Antonarakis ES (2012) Current status of immunological approaches for the treatment of prostate cancer. Current opinion in urology.
4. Di Lorenzo G, Buonerba C, Kantoff PW, (2011) Immunotherapy for the treatment of prostate cancer. Nature reviews Clinical oncology 8: 551-561.
5. Rosenberg SA, (2011) Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nature reviews Clinical oncology 8: 577-585.
6. Lesterhuis WJ, Haanen JB, Punt CJ, (2011) Cancer immunotherapy-revisited. Nature reviews Drug discovery 10: 591-600.
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine 363: 711-723.
8. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England journal of medicine 363: 411-422.
9. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, et al. (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. The New England journal of medicine 364: 2119-2127.
10. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T, (2012) Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482: 405-409.
11. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, et al. (2008) Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322: 1097-1100.
12. Lundwall A, Lilja H, (1987) Molecular cloning of human prostate specific antigen cDNA. FEBS letters 214: 317-322.
13. Oesterling JE, (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. The Journal of urology 145: 907-923.
14. Xu J, Kalos M, Stolk JA, Zasloff EJ, Zhang X, et al. (2001) Identification and characterization of prostein, a novel prostate-specific protein. Cancer research 61: 1563-1568.
15. Kalos M, Askaa J, Hylander BL, Repasky EA, Cai F, et al. (2004) Prostein expression is highly restricted to normal and malignant prostate tissues. The Prostate 60: 246-256.
16. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, et al. (2000) Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19: 1288-1296.
17. Kawakami M, Nakayama J, (1997) Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer research 57: 2321-2324.
18. Su SL, Huang IP, Fair WR, Powell CT, Heston WD, (1995) Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer research 55: 1441-1443.
19. Israeli RS, Powell CT, Fair WR, Heston WD, (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer research 53: 227-230.
20. Solin T, Kontturi M, Pohlmann R, Vihko P, (1990) Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses. Biochimica et biophysica acta 1048: 72-77.
21. Tsavaler L, Shapero MH, Morkowski S, Laus R, (2001) Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer research 61: 3760-3769.
22. Kiessling A, Fussel S, Wehner R, Bachmann M, Wirth MP, et al. (2008) Advances in specific immunotherapy for prostate cancer. European urology 53: 694-708.
23. Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, et al. (2000) PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer research 60: 6568-6572.
24. Yuan TT, Toy P, McClary JA, Lin RJ, Miyamoto NG, et al. (2001) Cloning and genetic characterization of an evolutionarily conserved human olfactory receptor that is differentially expressed across species. Gene 278: 41-51.
25. Weng J, Wang J, Cai Y, Stafford LJ, Mitchell D, et al. (2005) Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. International journal of cancer Journal international du cancer 113: 811-818.
26. Hammond AS, Klein MR, Corrah T, Fox A, Jaye A, et al. (2005) Mycobacterium tuberculosis genome-wide screen exposes multiple CD8 T cell epitopes. Clinical and experimental immunology 140: 109-116.
27. Wang M, Lamberth K, Harndahl M, Roder G, Stryhn A, et al. (2007) CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine 25: 2823-2831.
28. Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF, (2001) CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proceedings of the National Academy of Sciences of the United States of America 98: 3964-3969.
29. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA, (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. Journal of immunotherapy 26: 332-342.
30. Weng J, Ma W, Mitchell D, Zhang J, Liu M, (2005) Regulation of human prostate-specific G-protein coupled receptor, PSGR, by two distinct promoters and growth factors. Journal of cellular biochemistry 96: 1034-1048.
31. Carlsson B, Forsberg O, Bengtsson M, Totterman TH, Essand M, (2007) Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy. The Prostate 67: 389-395.
32. Van den Eynde BJ, Boon T, (1997) Tumor antigens recognized by T lymphocytes. International journal of clinical & laboratory research 27: 81-86.
33. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A, (1994) Tumor antigens recognized by T lymphocytes. Annual review of immunology 12: 337-365.
34. Novellino L, Castelli C, Parmiani G, (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer immunology, immunotherapy: CII 54: 187-207.
35. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, et al. (1998) Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. International journal of cancer Journal international du cancer 75: 517-524.
36. Albino AP, Lloyd KO, Houghton AN, Oettgen HF, Old LJ, (1981) Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. The Journal of experimental medicine 154: 1764-1778.
37. Mellman I, Coukos G, Dranoff G, (2011) Cancer immunotherapy comes of age. Nature 480: 480-489.